» Articles » PMID: 37395921

Melatonin Synergistically Enhances Docetaxel Induced Endoplasmic Reticulum Stress to Promote Apoptosis by Suppressing NF-κB Activation in Cervical Cancer

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2023 Jul 3
PMID 37395921
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer is the fourth most common malignancy in women globally. Although chemotherapy significantly improves the survival of cervical cancer patients, the development of drug resistance is inevitable. In the present study, our study showed that melatonin suppressed the proliferation, cell survival, colony formation, and the ability of adhering to fibronectin in cervical cancer cells. Our data suggested that docetaxel insensitivity was caused by NF-κB pathway activation, and followed by reducing endoplasmic reticulum stress and apoptosis. We showed that melatonin functioned as an oncostatic agent via inhibition of NF-κB signaling in cervical cancer cells. Interestingly, melatonin not only reduced the basal and inducible NF-κB pathway activation, but also prevented docetaxel induced NF-κB pathway activation by stabilizing IκBα protein. Importantly, inhibition of NF-κB pathway activation by melatonin abrogated the protective effect of NF-κB activation on docetaxel provoked endoplasmic reticulum stress, and further enhanced endoplasmic reticulum stress and apoptosis to produce synergistic oncostatic effects in cervical cancer cells. In summary, we revealed that melatonin was a novel agent to enhance docetaxel sensitivity by abolishing NF-κB activation and aggravating endoplasmic reticulum stress. Our results might provide a rationale for the clinical application of melatonin to overcome docetaxel resistance in cervical cancer patients.

Citing Articles

(Nano)biotechnological approaches in the treatment of cervical cancer: integration of engineering and biology.

Xie W, Xu Z Front Immunol. 2024; 15:1461894.

PMID: 39346915 PMC: 11427397. DOI: 10.3389/fimmu.2024.1461894.


Melatonin/Sericin Wound Healing Patches: Implications for Melanoma Therapy.

Adamiak K, Gaida V, Schafer J, Bosse L, Diemer C, Reiter R Int J Mol Sci. 2024; 25(9).

PMID: 38732075 PMC: 11084828. DOI: 10.3390/ijms25094858.


Melanogenesis Is Directly Affected by Metabolites of Melatonin in Human Melanoma Cells.

Moller J, Linowiecka K, Gagat M, Brozyna A, Foksinski M, Wolnicka-Glubisz A Int J Mol Sci. 2023; 24(19).

PMID: 37834395 PMC: 10573520. DOI: 10.3390/ijms241914947.

References
1.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

2.
Burmeister C, Khan S, Schafer G, Mbatani N, Adams T, Moodley J . Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022; 13:200238. PMC: 9062473. DOI: 10.1016/j.tvr.2022.200238. View

3.
Tilborghs S, Corthouts J, Verhoeven Y, Arias D, Rolfo C, Trinh X . The role of Nuclear Factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol. 2017; 120:141-150. DOI: 10.1016/j.critrevonc.2017.11.001. View

4.
Staudt L . Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010; 2(6):a000109. PMC: 2869521. DOI: 10.1101/cshperspect.a000109. View

5.
Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood W . Targeting the NF-κB Pathway as a Combination Therapy for Advanced Thyroid Cancer. PLoS One. 2015; 10(8):e0134901. PMC: 4532464. DOI: 10.1371/journal.pone.0134901. View